following an abbreviated submission:
brigatinib (Alunbrig®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
Brigatinib offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors for this indication.
Medicines within this therapeutic class have been accepted via the orphan process for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice648KB (PDF)
- Medicine name:
- brigatinib (Alunbrig)
- SMC ID:
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 18 January 2021